Cowen and Company’s Fate Therapeutics FATE Stock Holding History

Cowen and Company’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$151K	–	608
2022 Q4	$151K	Buy	+15,000	New	+$282K	0.02%	187

Other funds holding FATE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Cowen and Company's FATE Position: Q1 2023 in Review

Cowen and Company sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 15,000 shares — an estimated $151K sold.

Cowen and Company first reported a position in FATE in Q4 2022 and held it in 1 quarter. The position peaked at $151K in Q4 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

Cowen and Company reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 15,000 Fate Therapeutics shares in Q1 2023, an estimated $151K.
Cowen and Company first reported a position in Fate Therapeutics in Q4 2022 and held it in 1 quarter.
Cowen and Company's Fate Therapeutics position peaked at $151K in Q4 2022.
181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.